The October issue of Nature Reviews Clinical Oncology

Diana Romero posted on LinkedIn:

“The October issue of Nature Reviews Clinical Oncology was just published today:

As you may guess from the cover that Lara Crow has drawn for us, in this issue you can learn about the utility of tumour mutational burden in clinical oncology – you’ve probably heard this term if you attend talks discussing immunotherapies, but how to interpret the results?

You can also read about therapies for virus-associated cancers, and for hormone receptor-positive breast cancer, plus a few shorter pieces on recent studies – are they practice changing or not?

Tumour mutational burden: clinical utility, challenges and emerging improvements

Authors: Jan Budczies, Daniel Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor, Peter Schirmacher, Solange Peters, Alwin Krämer, Petros Christopoulos, Albrecht Stenzinger.”

Source: Diana Romero/LinkedIn

Diana Romero is the Chief Editor of Nature Reviews Clinical Oncology. Diana obtained her PhD in Biochemistry from the Universidad Autonoma de Madrid (Spain), where she studied the role of TGF-β in cancer progression in Miguel Quintanilla’s group. She joined Calvin Vary’s laboratory at Maine Medical Center Research Institute (US) for her first postdoctoral project, which was related to TGF-β receptor signaling and prostate cancer. In 2010 she moved to Robert Kypta’s group at Imperial College London (UK) as a postdoc. While maintaining her interest in prostate cancer, her project focused on Dickkopf-3 signaling. Diana joined the Nature Reviews Clinical Oncology team in July 2015, and became Chief Editor of the journal in September 2017.